001027025 001__ 1027025
001027025 005__ 20250204113901.0
001027025 0247_ $$2doi$$a10.1016/j.msard.2024.105664
001027025 0247_ $$2ISSN$$a2211-0348
001027025 0247_ $$2ISSN$$a2211-0356
001027025 0247_ $$2datacite_doi$$a10.34734/FZJ-2024-03591
001027025 0247_ $$2pmid$$a38735204
001027025 0247_ $$2WOS$$aWOS:001243115500001
001027025 037__ $$aFZJ-2024-03591
001027025 082__ $$a610
001027025 1001_ $$00000-0003-0707-0485$$aSchweitzer, Finja$$b0
001027025 245__ $$aAbsence of JC polyomavirus in stool samples of patients with multiple sclerosis despite high anti-JCV antibodies in serum
001027025 260__ $$aAmsterdam [u.a.]$$bElsevier$$c2024
001027025 3367_ $$2DRIVER$$aarticle
001027025 3367_ $$2DataCite$$aOutput Types/Journal article
001027025 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1717995927_11605
001027025 3367_ $$2BibTeX$$aARTICLE
001027025 3367_ $$2ORCID$$aJOURNAL_ARTICLE
001027025 3367_ $$00$$2EndNote$$aJournal Article
001027025 520__ $$aBackground: Natalizumab is an effective treatment for relapsing multiple sclerosis (MS). During therapy, individualsare at increased risk of developing progressive multifocal leukoencephalopathy (PML). So far, therelevant reservoir for PML-type JC polyomavirus (JCV) remains elusive. We here tested if the detection of JCVDNAin stool of persons with MS treated with natalizumab could be a future tool for PML risk assessment.Methods: The presence of JCV-DNA in stool, urine, and whole blood of MS patients treated with natalizumab andknown serum anti-JCV antibodies index values (IV) was studied. Different DNA extraction methods, real-time(RT) and droplet digital (dd) PCR techniques were compared. JCV isolates were screened for PML-associatedvariants by sequencing.Results: Thirty MS patients treated with natalizumab were screened. For 21 patients, blood, stool, and urinesamples were available. These patients were stratified according to their serum anti-JCV antibody IV (high (>1.5,n = 12); medium (1.5–0.9, n = 2); low (<0.9, n = 1); negative (n = 6)). JCV-DNA could not be detected in thewhole blood or stool samples. Four urine samples had measurable JCV-DNA, ranging from 1.71×104–1.07×108international units (IU)/mL detected by RT-PCR, corresponding to 4.62×104–9.85×106 copies/mL measured byddPCR. All JCV variants were wild-type and derived from patients with high antibody IV.Conclusion: Stool-specific DNA extraction methods provided the highest quality of DNA, while the sensitivity ofddPCR and RT- PCR was comparable. Our findings do not support assessing stool samples for PML risk stratificationin persons with MS. Further studies are needed to explore where PML-associated viral variants arise.
001027025 536__ $$0G:(DE-HGF)POF4-5251$$a5251 - Multilevel Brain Organization and Variability (POF4-525)$$cPOF4-525$$fPOF IV$$x0
001027025 536__ $$0G:(GEPRIS)501362249$$aDFG project 501362249 - Progressive multifokale Leukenzephalopathie: Biomarker für eine frühzeitige Diagnose, für die Risikovorhersage unter Immuntherapien sowie für ein Ansprechen auf eine zielgerichtete Therapie (501362249)$$c501362249$$x1
001027025 588__ $$aDataset connected to CrossRef, Journals: juser.fz-juelich.de
001027025 7001_ $$0P:(DE-HGF)0$$aLadwig, Anne$$b1
001027025 7001_ $$0P:(DE-HGF)0$$aOpala, Sarah$$b2
001027025 7001_ $$0P:(DE-HGF)0$$aLaurent, Sarah$$b3
001027025 7001_ $$0P:(DE-HGF)0$$aSchroeter, Michael$$b4
001027025 7001_ $$0P:(DE-HGF)0$$aGoelz, Susan$$b5
001027025 7001_ $$0P:(DE-Juel1)131720$$aFink, Gereon R.$$b6$$ufzj
001027025 7001_ $$0P:(DE-HGF)0$$aWieland, Ulrike$$b7
001027025 7001_ $$0P:(DE-HGF)0$$aSilling, Steffi$$b8
001027025 7001_ $$00000-0002-3510-9255$$aWarnke, Clemens$$b9$$eCorresponding author
001027025 773__ $$0PERI:(DE-600)2645330-7$$a10.1016/j.msard.2024.105664$$gVol. 87, p. 105664 -$$p105664 -$$tMultiple Sclerosis and Related Disorders$$v87$$x2211-0348$$y2024
001027025 8564_ $$uhttps://juser.fz-juelich.de/record/1027025/files/PDF.pdf$$yOpenAccess
001027025 8564_ $$uhttps://juser.fz-juelich.de/record/1027025/files/PDF.gif?subformat=icon$$xicon$$yOpenAccess
001027025 8564_ $$uhttps://juser.fz-juelich.de/record/1027025/files/PDF.jpg?subformat=icon-1440$$xicon-1440$$yOpenAccess
001027025 8564_ $$uhttps://juser.fz-juelich.de/record/1027025/files/PDF.jpg?subformat=icon-180$$xicon-180$$yOpenAccess
001027025 8564_ $$uhttps://juser.fz-juelich.de/record/1027025/files/PDF.jpg?subformat=icon-640$$xicon-640$$yOpenAccess
001027025 909CO $$ooai:juser.fz-juelich.de:1027025$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
001027025 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131720$$aForschungszentrum Jülich$$b6$$kFZJ
001027025 9131_ $$0G:(DE-HGF)POF4-525$$1G:(DE-HGF)POF4-520$$2G:(DE-HGF)POF4-500$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$9G:(DE-HGF)POF4-5251$$aDE-HGF$$bKey Technologies$$lNatural, Artificial and Cognitive Information Processing$$vDecoding Brain Organization and Dysfunction$$x0
001027025 9141_ $$y2024
001027025 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
001027025 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-08-26
001027025 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
001027025 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-08-26
001027025 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bMULT SCLER RELAT DIS : 2022$$d2025-01-06
001027025 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-01-06
001027025 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-01-06
001027025 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-01-06
001027025 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-01-06
001027025 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2025-01-06
001027025 920__ $$lyes
001027025 9201_ $$0I:(DE-Juel1)INM-3-20090406$$kINM-3$$lKognitive Neurowissenschaften$$x0
001027025 980__ $$ajournal
001027025 980__ $$aVDB
001027025 980__ $$aUNRESTRICTED
001027025 980__ $$aI:(DE-Juel1)INM-3-20090406
001027025 9801_ $$aFullTexts